Cycle Pharmaceuticals announced that it has signed an agreement with Catalent to develop innovative formulations targeting rare disease patients.
Pandion Therapeutics has signed a license and collaboration deal worth up to $795m with Japan-based Astellas Pharma to research, develop, and commercialise locally acting immunomodulators for autoimmune diseases of the pancreas.
Gilead Sciences and Glympse Bio announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical programme.
Takeda Pharmaceutical has signed a deal worth up to $420m with COUR Pharmaceutical Development to acquire an exclusive global license to develop and commercialise the latter’s CNP-101 (TAK-101).
Zealand Pharma, a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the acquisition of Encycle Therapeutics, a private Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of macrocyclic peptides exhibiting enhanced drug-like properties.
Verseau Therapeutics, Inc. (“Verseau”) launched with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua Capital.
Alexion Pharmaceuticals has agreed to acquire clinical-stage biopharmaceutical company Achillion Pharmaceuticals in a deal valued at around $930m.
CRISPR Therapeutics and KSQ Therapeutics have signed license agreement to advance their respective cell therapy programmes in oncology.
Belgium-based biopharmaceutical firm UCB has agreed to acquire US-based clinical-stage biopharmaceutical company Ra Pharmaceuticals in a deal valued at around $2.1bn.
Alexion Pharmaceuticals and Stealth BioTherapeutics have announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.